Efficacy and safety of CHF6001, a novel inhaled PDE4 inhibitor in COPD: the PIONEER study

Overview of attention for article published in Respiratory Research, September 2020

Altmetric Badge

Mentioned by

twitter: 2 X users

Citations

dimensions_citation: 23 Dimensions

Readers on

mendeley: 50 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 3 X posts from 2 X users, with an upper bound of 4,331 followers.

PDE4 inhibition benefits #aecopd rate in chronic bronchitis if Eos>150. Caveat that it's a post hoc analysis but consistent with effects of roflumilast

20 Nov 2020

Reply Repost Favourite

Efficacy and safety of CHF6001, a novel inhaled PDE4 inhibitor in COPD: the PIONEER study #WorldCOPDDay https://t.co/DS2lfeV7JH

18 Nov 2020

Reply Repost Favourite

New article: Efficacy and safety of CHF6001, a novel inhaled PDE4 inhibitor in #COPD: the PIONEER study https://t.co/DS2lfeV7JH

23 Sep 2020

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.